PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 1823-1832

  Damjanac, Milena ^a   Page, Guylène ^a   Ragot, Stéphanie ^b   Laborie, Guillaume ^a   Gil, Roger ^a,b   Hugon, Jacques ^c   Paccalin, Marc ^a,b  

^a UNIVERSITÉ DE POITIERS   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Alzheimer's disease; Lymphocytes; MMSE; P53; PKR; Redd1

Indexed keywords

BIOLOGICAL MARKER; DDIT4 PROTEIN, HUMAN; PRIMER DNA; PROTEIN KINASE R; PROTEIN P53; TRANSCRIPTION FACTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD; COGNITIVE DEFECT; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; LYMPHOCYTE; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BASE SEQUENCE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; COGNITION DISORDERS; DNA PRIMERS; EIF-2 KINASE; FEMALE; HUMANS; LYMPHOCYTES; MALE; PROTEIN BIOSYNTHESIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

MAMMALIA;

EID: 70349323831     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00688.x     Document Type: Article

References (60)

1. Rojo LE, Fernandez JA, Maccioni AA, et al. Neuroin-flammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch Med Res. 2008 39 : 1 16.
2. Shi Q, Gibson GE. Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Dis Assoc Disord. 2007 21 : 276 291.
3. Pannaccione A, Boscia F, Scorziello A, et al. Up-regulation and increased activity of KV3.4 channels and their accessory subunit MinK-related peptide 2 induced by amyloid peptide are involved in apoptotic neuronal death. Mol Pharmacol. 2007 72 : 665 673.
4. Shen Y, He P, Zhong Z, et al. Distinct destructive signal pathways of neuronal death in Alzheimer's disease. Trends Mol Med. 2006 12 : 574 579.
5. van Leeuwen FW, Hol EM, Fischer DF. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system. J Alzheimers Dis. 2006 9 : 319 325.
6. Clemens MJ, Elia A. The double-stranded RNA-dependent protein kinase PKR: structure and function. J Interferon Cytokine Res. 1997 17 : 503 524.
7. Williams BR. PKR; a sentinel kinase for cellular stress. Oncogene. 1999 18 : 6112 6120.
8. Peel AL. PKR activation in neurodegenerative disease. J Neuropathol Exp Neurol. 2004 63 : 97 105.
9. Onuki R, Bando Y, Suyama E, et al. An RNA-dependent protein kinase is involved in tunicamycin-induced apoptosis and Alzheimer's disease. EMBO J. 2004 23 : 959 968.
10. Chang RC, Wong AK, Ng HK, et al. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport. 2002 13 : 2429 2432.
11. Clemens MJ. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene. 2004 23 : 3180 3188.
12. Raught B, Gingras AC, Sonenberg N. The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA. 2001 98 : 7037 7044.
13. Dufner A, Thomas G. Ribosomal S6 kinase signaling and the control of translation. Exp Cell Res. 1999 253 : 100 109.
14. Paccalin M, Pain-Barc S, Pluchon C, et al. The relation between p70S6k expression in lymphocytes and the decline of cognitive test scores in patients with Alzheimer disease. Arch Intern Med. 2005 165 : 2428 2429.
15. Paccalin M, Pain-Barc S, Pluchon C, et al. Activated mTOR and PKR kinases in lymphocytes correlate with memory and cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord. 2006 22 : 320 326.
16. Paccalin M, Al Khidir F, Barc SP, et al. Peripheral p70S6k levels and emotional memory in patients with Alzheimer's disease. Neurosci Lett. 2006 410 : 162 164.
17. Lafay-Chebassier C, Paccalin M, Page G, et al. mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem. 2005 94 : 215 225.
18. Baltzis D, Pluquet O, Papadakis AI, et al. The eIF2alpha kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. J Biol Chem. 2007 282 : 31675 31687.
19. Cuddihy AR, Wong AH, Tam NW, et al. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene. 1999 18 : 2690 2702.
20. Jin HO, An S, Lee HC, et al. Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. Cell Signal. 2007 19 : 1393 1403.
21. Ellisen LW, Ramsayer KD, Johannessen CM, et al. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002 10 : 995 1005.
22. Corradetti MN, Inoki K, Guan KL. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. 2005 280 : 9769 9772.
23. Sofer A, Lei K, Johannessen CM, et al. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol. 2005 25 : 5834 5845.
24. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004 18 : 2893 2904.
25. Shoshani T, Faerman A, Mett I, et al. Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol Cell Biol. 2002 22 : 2283 2293.
26. Lanni C, Uberti D, Racchi M, et al. Unfolded p53: a potential biomarker for Alzheimer's disease. J Alzheimers Dis. 2007 12 : 93 9.
27. Lanni C, Racchi M, Mazzini G, et al. Conformationally altered p53: a novel Alzheimer's disease marker Mol Psychiatry. 2007.
28. Tang K, Hynan LS, Baskin F, et al. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer's disease. J Neurol Sci. 2006 240 : 53 8.
29. Eckert A, Schindowski K, Leutner S, et al. Alzheimer's disease-like alterations in peripheral cells from presenilin-1 transgenic mice. Neurobiol Dis. 2001 8 : 331 342.
30. Schindowski K, Kratzsch T, Peters J, et al. Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease. Neuro-molecular Med. 2003 4 : 161 178.
31. Uberti D, Belloni M, Grilli M, et al. Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino acids. Eur J Neurosci. 1998 10 : 246 254.
32. McGahan L, Hakim AM, Robertson GS. Hippocampal Myc and p53 expression following transient global ischemia. Brain Res Mol Brain Res. 1998 56 : 133 145.
33. Culmsee C, Zhu X, Yu QS, et al. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem. 2001 77 : 220 228.
34. Gilman CP, Chan SL, Guo Z, et al. p53 is present in synapses where it mediates mitochondrial dysfunction and synaptic degeneration in response to DNA damage, and oxidative and excitotoxic insults. Neuromolecular Med. 2003 3 : 159 172.
35. Biswas SC, Ryu E, Park C, et al. Puma and p53 play required roles in death evoked in a cellular model of Parkinson disease. Neurochem Res. 2005 30 : 839 845.
36. Nair VD. Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Apoptosis. 2006 11 : 955 966.
37. Nair VD, McNaught KS, Gonzalez-Maeso J, et al. p53 mediates nontranscriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem. 2006 281 : 39550 39560.
38. Sajan FD, Martiniuk F, Marcus DL, et al. Apoptotic gene expression in Alzheimer's disease hippocampal tissue. Am J Alzheimers Dis Other Demen. 2007 22 : 319 328.
39. de la Monte SM, Sohn YK, Wands JR. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci. 1997 152 : 73 83.
40. Kitamura Y, Shimohama S, Kamoshima W, et al. Changes of p53 in the brains of patients with Alzheimer's disease. Biochem Biophys Res Commun. 1997 232 : 418 421.
41. Hooper C, Meimaridou E, Tavassoli M, et al. p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett. 2007 418 : 34 7.
42. Checler F, Sunyach C, Pardossi-Piquard R, et al. The gamma/epsilon- secretase-derived APP intracellular domain fragments regulate p53. Curr Alzheimer Res. 2007 4 : 423 426.
43. Alves da Costa C, Sunyach C, Pardossi-Piquard R, et al. Presenilin-dependent gamma-secretase-mediated control of p53-associated cell death in Alzheimer's disease. J Neurosci. 2006 26 : 6377 6385.
44. Ohyagi Y, Asahara H, Chui DH, et al. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J. 2005 19 : 255 257.
45. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006 13 : 941 950.
46. Uberti D, Lanni C, Carsana T, et al. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients. Neurobiol Aging. 2006 27 : 1193 1201.
47. Uberti D, Cenini G, Olivari L, et al. Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J Neurochem. 2007 103 : 322 333.
48. Gil J, Esteban M. Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis. 2000 5 : 107 114. (Pubitemid 30399384)
49. Opferman JT, Zambetti GP. Translational research? Ribosome integrity and a new p53 tumor suppressor checkpoint. Cell Death Differ. 2006 13 : 898 901.
50. Horton LE, Bushell M, Barth-Baus D, et al. p53 activation results in rapid dephosphorylation of the eIF4E-binding protein 4E-BP1, inhibition of ribosomal protein S6 kinase and inhibition of translation initiation. Oncogene. 2002 21 : 5325 5334.
51. Lombardi VR, Garcia M, Rey L, et al. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals. J Neuroimmunol. 1999 97 : 163 171.
52. Shalit F, Sredni B, Brodie C, et al. T lymphocyte subpopulations and activation markers correlate with severity of Alzheimer's disease. Clin Immunol Immunopathol. 1995 75 : 246 250.
53. Ellisen LW. Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle. 2005 4 : 1500 1502.
54. Jozwiak J, Jozwiak S, Grzela T, et al. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med. 2005 7 : 287 296.
55. Wang H, Kubica N, Ellisen LW, et al. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem. 2006 281 : 39128 39134.
56. Kimball SR, Do AN, Kutzler L, et al. Rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis. J Biol Chem. 2008 283 : 3465 3475.
57. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA. 2005 102 : 8204 8209.
58. Kim JR, Lee SR, Chung HJ, et al. Identification of amyloid beta-peptide responsive genes by cDNA microarray technology: involvement of RTP801 in amyloid beta-peptide toxicity. Exp Mol Med. 2003 35 : 403 411.
59. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med. 2007 13 : 1359 1362.
60. Page G, Rioux Bilan A, Ingrand S, et al. Activated double-stranded RNA-dependent protein kinase and neuronal death in models of Alzheimer's disease. Neuroscience. 2006 139 : 1343 1354.